| MeSH term | MeSH ID | Detail |
|---|---|---|
| Priapism | D011317 | 1 associated lipids |
| Vulvar Lichen Sclerosus | D007724 | 1 associated lipids |
| Cardiomyopathy, Restrictive | D002313 | 1 associated lipids |
| Paraparesis, Tropical Spastic | D015493 | 1 associated lipids |
| Neurodermatitis | D009450 | 1 associated lipids |
| Posterior Leukoencephalopathy Syndrome | D054038 | 1 associated lipids |
| Ichthyosiform Erythroderma, Congenital | D016113 | 1 associated lipids |
| Panniculitis, Lupus Erythematosus | D015435 | 1 associated lipids |
| Retrognathia | D063173 | 1 associated lipids |
| Mediastinal Diseases | D008477 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Morris RE | In vivo immunopharmacology of the macrolides FK 506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development, and use. | 1991 | Transplant. Proc. | pmid:1721257 |
| Kobayashi M et al. | FK 506 assay past and present--characteristics of FK 506 ELISA. | 1991 | Transplant. Proc. | pmid:1721258 |
| Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
| Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
| Loréal O et al. | FK 506 is less cytotoxic than cyclosporine to human and rat hepatocytes in vitro. | 1991 | Transplant. Proc. | pmid:1721289 |
| McCauley J et al. | Cyclosporine and FK 506 induced inhibition of renal epithelial cell proliferation. | 1991 | Transplant. Proc. | pmid:1721290 |
| McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
| Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
| Schreiber SL et al. | Immunophilin-ligand complexes as probes of intracellular signaling pathways. | 1991 | Transplant. Proc. | pmid:1721293 |
| Fukuzawa M et al. | Effect of FK 506 on CD4+ and CD8+ T-cell function in vivo. | 1991 | Transplant. Proc. | pmid:1721321 |
| Takaori K et al. | Effects of FK 506 on in vivo immunity in comparison to cyclosporine. | 1991 | Transplant. Proc. | pmid:1721322 |
| Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
| Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
| Torre-Cisneros J et al. | The spectrum of aspergillosis in liver transplant patients: comparison of FK 506 and cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721353 |
| Starzl TE et al. | Hepatotrophic effects of FK506 in dogs. | 1991 | Transplantation | pmid:1702912 |
| Paul AA et al. | CMV retinitis and the use of FK 506. | 1991 | Transplant. Proc. | pmid:1721354 |
| Keicho N et al. | Effects of an immunosuppressant, FK506, on interleukin 1 alpha production by human macrophages and a macrophage-like cell line, U937. | 1991 | Cell. Immunol. | pmid:1703047 |
| Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
| White DJ | FK506: the promise and the paradox. | 1991 | Clin. Exp. Immunol. | pmid:1703053 |
| Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
| Frayha HH et al. | Lymphoproliferative disorder in a liver transplant patient on FK 506. | 1991 | Lancet | pmid:1703258 |
| McCauley J et al. | Renal function after conversion from cyclosporine to FK 506 in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721387 |
| Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
| Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
| Schmidt RJ et al. | Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721390 |
| Tzakis AG et al. | FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721416 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
| Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
| Iwaki Y et al. | Replacement of donor lymphoid tissue in small-bowel transplants. | 1991 | Lancet | pmid:1707470 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Davies CB et al. | Effects of donor-specific transfusion, cyclosporine A and FK 506 on rat cardiac allograft survival. | 1991 | Transplant. Proc. | pmid:1721448 |
| Abu-Elmagd K et al. | FK 506: a new therapeutic agent for severe recalcitrant psoriasis. | 1991 | Transplant. Proc. | pmid:1721449 |
| Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
| Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
| Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
| Farley DE et al. | The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. | 1991 | Transplantation | pmid:1713360 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Jiang H et al. | Effect of FK-506 on heart allograft survival in the highly sensitized recipient rats as compared with ciclosporin and 15-deoxyspergualin. | 1991 | Eur Surg Res | pmid:1723683 |
| Pezze JL and Whiteman K | Transplantation's newest weapon FK 506. | 1991 | Am J Nurs | pmid:1716857 |
| Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
| Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
| Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
| Sakai K et al. | [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. | 1991 | No To Shinkei | pmid:1716937 |
| Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
| Altmeyer A et al. | Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. | 1991 | Int. J. Immunopharmacol. | pmid:1726093 |
| Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |
| Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |